The new FDA Modernization Act 2.0 authorizes the use of certain alternatives to animal testing, including cell-based assays, to investigate the safety and effectiveness of a drug.
DefiniGEN’s vision is to provide highly predictive cell-based models of liver disease to the drug development industry. These models will be used to reduce the chances of a medicine failing at the clinical stage and reduce the number of animals used in safety assessment.
DefiniGEN’s platform for drug screening enables the replacement of animal models with human relevant liver disease models with supporting bioassays that can accurately evaluate compound efficacy.
- For further information about DefiniGEN’s Screening Services click here
- To learn more about Alpha-1 Antitrypsin Deficiency Validated model click here
- Want to discuss your project specific requirements? Get in touch today